Hamburg Tries To “Cope” With FDA Budget, Emphasizes Predictability
This article was originally published in The Tan Sheet
Executive Summary
The commissioner says FDA cannot operate effectively without predictable budgets, just as industry needs consistent FDA policy and actions for successful drug development. Making sequestered user fees available could be accomplished in fiscal 2014 budget negotiations.
You may also be interested in...
FDA Shutdown Lands Hard On CFSAN-Regulated Industries
The federal shutdown interrupts FDA’s increasing enforcement against firms marketing violative supplement products in addition to slowing drug application evaluations and facility inspections. FDA would retain 8,180 staff members, about 55% of its total, mostly because they could be “paid from carryover funding.”
FDA Accelerated Approval For Rare Diseases Again Under Congressional Pressure
Letter being circulated by Rep. Bilirakis states the agency’s draft expedited approval guidance does not provide clarity for rare disease sponsors to use accelerated approval.
FDA Budget Faces $319 Million Cut Under Sequestration
The estimated reduction, included in the White House OMB’s report to Congress, is equal to the cost of 900 to 1,200 agency employees, an agency advocate says. The across-the-board cuts loom with the failure of the congressional Super Committee to find $1.2 trillion in cuts over 10 years.